Medical Oncology

, Volume 29, Issue 4, pp 2567–2569 | Cite as

Severe visual loss in a breast cancer patient on chemotherapy

  • Joan Giralt
  • Amanda ReyEmail author
  • Rafael Villanueva
  • Socorro Alforja
  • Ricardo P. Casaroli-Marano
Short Communication


We report the case of a 44-year-old woman with breast cancer who experienced visual loss and altered color vision after two cycles of chemotherapy with 5 fluorouracil, epirubicin, and cyclophosphamide. She was referred to our Ophthalmology department with suspicion of toxic optic neuropathy. Clinical examination revealed altered color perception in the right side along with a central scotoma on visual field testing. Electrophysiological tests including visual evoked potentials were normal. Funduscopic examination was compatible with bilateral serous retinal detachment. Optical coherence tomography (OCT) demonstrated serous detachment of the retina bilaterally associated with small detachments of the pigment epithelium. Additionally, fluorescein angiography (FA) revealed multiple sites of fluorescein leakage. After 2 months, the clinical findings remained unchanged. An oncological consultation revealed that the patient had received two cycles of intravenous dexamethasone (4 mg) for 3 days in order to treat chemotherapy-induced nausea and vomiting. A diagnosis of steroid-induced central serous chorioretinopathy was then made. At the last follow-up visit, the patient’s visual acuity, color vision, OCT, and FA were back to normal. To our knowledge, this is the first reported case of bilateral severe visual loss secondary to corticosteroid-induced central serous chorioretinopathy in a patient on breast cancer therapy. With the increase use of anti-emetic drugs in cancer chemotherapy, we have to be aware of this possible visual complication.


Central serous chorioretinopathy Retinal detachment Retina Chemotherapeutic drugs Retinopathy Retinal pigment epithelium detachment 


Conflict of interest

The authors report no conflicts of interest.


  1. 1.
    Wang M, Munch IC, Hasler PW, et al. Central serous chorioretinopathy. Acta Ophthalmol. 2008;86:126–45.PubMedCrossRefGoogle Scholar
  2. 2.
    Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol. 2002;47:431–48.PubMedCrossRefGoogle Scholar
  3. 3.
    Levy J, Marcus M, Belfair N, et al. Central serous chorioretinopathy in patients receiving systemic corticosteroid therapy. Can J Ophthalmol. 2005;40:217–21.Google Scholar
  4. 4.
    Wakakura M, Song E, Ishikawa S. Corticosteroid-induced central serous chorioretinopathy. Jpn J Ophthalmol. 1997;41:180–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Joo JL, Lee SY, Ang CL. Can long-term corticosteroids lead to blindness? A case series of central serous chorioretinopathy induced by corticosteroids. Ann Acad Med Singap. 2006;35:496–9.Google Scholar
  6. 6.
    Oliaei F, Rasoulinejad SB. An ophthalmological complication: central serous chorioretinopathy in a renal transplant recipient. Transplant Proc. 2007;39:1134–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Chan WM, Lam DSC, Lai TY, et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol. 2003;87:1453–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Lanzetta P, Furlan F, Morgante L, et al. Nonvisible subthreshold micropulse diode laser (810 nm) treatment of central serous chorioretinopathy. A pilot study. Eur J Ophthalmol. 2008;18:934–40.PubMedGoogle Scholar
  9. 9.
    Herrstedt J, Dombemowsky P. Anti-emetic therapy in cancer chemotherapy: current status. Basic Clin Pharmacol Toxicol. 2007;101:143–50.PubMedCrossRefGoogle Scholar
  10. 10.
    Herrstedt J. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting. Expert Opin Drug Saf. 2004;3:231–48.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Joan Giralt
    • 1
  • Amanda Rey
    • 1
    Email author
  • Rafael Villanueva
    • 2
  • Socorro Alforja
    • 1
  • Ricardo P. Casaroli-Marano
    • 1
  1. 1.Department of Ophthalmology, Hospital ClinicUniversidad de BarcelonaBarcelonaSpain
  2. 2.Department of Oncology, Hospital ClinicUniversidad de BarcelonaBarcelonaSpain

Personalised recommendations